Trial · NCT01802333
Adverse events633
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 633
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anemia | Blood and lymphatic system disorders | Arm I (Standard Dose Cytarabine, Daunorubicin Hydrochloride) | 185 | 261 | |
| other | Anemia | Blood and lymphatic system disorders | Arm II (High-dose Cytarabine, Idarubicin) | 185 | 259 | |
| other | Anemia | Blood and lymphatic system disorders | Arm III (Vorinostat, High-dose Cytarabine, Idarubicin) | 137 | 211 | |
| other | Febrile neutropenia | Blood and lymphatic system disorders | Arm I (Standard Dose Cytarabine, Daunorubicin Hydrochloride) | 158 | 261 | |
| other | Febrile neutropenia | Blood and lymphatic system disorders | Arm II (High-dose Cytarabine, Idarubicin) | 170 | 259 | |
| other | Febrile neutropenia | Blood and lymphatic system disorders | Arm III (Vorinostat, High-dose Cytarabine, Idarubicin) | 120 | 211 | |
| other | Sinus bradycardia | Cardiac disorders | Arm I (Standard Dose Cytarabine, Daunorubicin Hydrochloride) | 11 | 261 | |
| other | Sinus bradycardia | Cardiac disorders | Arm II (High-dose Cytarabine, Idarubicin) | 9 | 259 | |
| other | Sinus bradycardia | Cardiac disorders | Arm III (Vorinostat, High-dose Cytarabine, Idarubicin) | 12 | 211 | |
| other | Sinus tachycardia | Cardiac disorders | Arm I (Standard Dose Cytarabine, Daunorubicin Hydrochloride) | 44 | 261 | |
| other | Sinus tachycardia | Cardiac disorders | Arm II (High-dose Cytarabine, Idarubicin) | 47 | 259 | |
| other | Sinus tachycardia | Cardiac disorders | Arm III (Vorinostat, High-dose Cytarabine, Idarubicin) | 30 | 211 | |
| other | Ear pain | Ear and labyrinth disorders | Arm I (Standard Dose Cytarabine, Daunorubicin Hydrochloride) | 16 | 261 | |
| other | Ear pain | Ear and labyrinth disorders | Arm II (High-dose Cytarabine, Idarubicin) | 7 | 259 | |
| other | Ear pain | Ear and labyrinth disorders | Arm III (Vorinostat, High-dose Cytarabine, Idarubicin) | 2 | 211 | |
| other | Blurred vision | Eye disorders | Arm I (Standard Dose Cytarabine, Daunorubicin Hydrochloride) | 15 | 261 | |
| other | Blurred vision | Eye disorders | Arm II (High-dose Cytarabine, Idarubicin) | 13 | 259 | |
| other | Blurred vision | Eye disorders | Arm III (Vorinostat, High-dose Cytarabine, Idarubicin) | 16 | 211 | |
| other | Eye disorders-Other | Eye disorders | Arm I (Standard Dose Cytarabine, Daunorubicin Hydrochloride) | 16 | 261 | |
| other | Eye disorders-Other | Eye disorders | Arm II (High-dose Cytarabine, Idarubicin) | 15 | 259 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01802333/events